Pharmaceutical Excipients 2016
DOI: 10.1002/9781118992432.ch3
|View full text |Cite
|
Sign up to set email alerts
|

Excipients and their Functionality for Enabling Technologies in Oral Dosage Forms

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2018
2018
2021
2021

Publication Types

Select...
4

Relationship

1
3

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 40 publications
0
2
0
Order By: Relevance
“…The typical structure of microcrystalline cellulose (labeled "a" in the figure) was observed as elongated filamentary structures with angular borders [49], while the lactose structures (labeled "b") were rather small, spherical and without angular edges. The structure of the matrix by itself, in combination with the structure of an excipient, influences the behavior of the sample; for example, the filamentous structures of the microcrystalline cellulose give greater force against abrasion, while the spherical lactose structures provide greater cohesion between the particles, allowing longer disintegration times [50][51][52].…”
Section: Scanning Electron Microscopy (Sem)mentioning
confidence: 99%
“…The typical structure of microcrystalline cellulose (labeled "a" in the figure) was observed as elongated filamentary structures with angular borders [49], while the lactose structures (labeled "b") were rather small, spherical and without angular edges. The structure of the matrix by itself, in combination with the structure of an excipient, influences the behavior of the sample; for example, the filamentous structures of the microcrystalline cellulose give greater force against abrasion, while the spherical lactose structures provide greater cohesion between the particles, allowing longer disintegration times [50][51][52].…”
Section: Scanning Electron Microscopy (Sem)mentioning
confidence: 99%
“…Hence, the selection of an enabling technology needs to balance bioavailability over stability and manufacturing aspects, especially in case of borderline solubility-limited drug candidates in between Biopharmaceutics Classification System BCS I and II or III and IV, respectively. Interactions between active pharmaceutical ingredients ( APIs ) and functional excipients are often employed to improve solubility and dissolution kinetics in enabling formulations ( Thakkar et al, 2016 ). However, the question remains whether excipients regarded as standard might establish similar interactions; subsequently, improvement of aqueous solubility when employed at unusual manufacturing process conditions.…”
Section: Introductionmentioning
confidence: 99%